scorecardresearch
Thursday, March 28, 2024
Support Our Journalism
HomeScienceJohnson & Johnson halts Covid vaccine trial due to unexplained illness in...

Johnson & Johnson halts Covid vaccine trial due to unexplained illness in one participant

While there are hundreds of Covid vaccines being developed, J&J is among a short list of vaccine makers who have progressed into final-stage human studies.

Follow Us :
Text Size:

Johnson & Johnson said its Covid-19 vaccine study has been temporarily halted after a clinical trial participant experienced an unexplained illness, the second time that a front-runner developer has paused a trial amid the intensifying race to create a viable immunization against the virus.

The New Brunswick, New Jersey-based company said in a statement late Monday the participant’s illness is being evaluated, and that it would share more information after further investigation. J&J’s statement confirmed an earlier report by health-care news provider STAT that the study was paused.

“We are committed to providing transparent updates throughout the clinical development process of our vaccine candidate,” J&J said in its statement. “Adverse events – illnesses, accidents, etc. – even those that are serious, are an expected part of any clinical study, especially large studies.”

While pauses in late-stage testing are routine in the pharmaceutical industry, J&J’s interruption may contribute to concerns over safety with Covid-19 vaccine research progressing at an unprecedented speed this year. British drugmaker AstraZeneca Plc last month temporarily stopped tests of its own vaccine candidate after a trial participant fell ill. That study has resumed in a number of countries, but remains halted in the U.S.

J&J executives will likely face questions about the trial halt Tuesday morning U.S. time when they present third-quarter earnings. Representatives for the U.S. Food and Drug Administration could not immediately be reached by phone or email for comment after business hours.

J&J’s setback is the latest reality check for a world anxiously awaiting a vaccine against the virus, which has sickened more than 37 million globally. It’s a reminder of how long it takes to bring a successful shot to market, despite promises from politicians and governments that a Covid-19 fix is around the corner.

The pursuit of a vaccine has become a political topic, with some observers concerned that U.S. President Donald Trump’s eagerness to see a shot authorized before the election could compromise the scientific process.

While there are hundreds of Covid-19 vaccines being developed around the world, J&J is among a small group of vaccine makers which have progressed into final-stage human studies. The company is dosing up to 60,000 volunteers in the first big trial of an Covid-19 inoculation that may work after just one shot.

AstraZeneca is still waiting for a decision from U.S. regulators on whether it can resume tests in the country after halting global trials on Sept. 6 due to concerns about a U.K. participant who became ill. Developed with Oxford University, that experimental vaccine has seen trials resume outside the U.S. in locations including the U.K. and South Africa.- Bloomberg


Also read: Moderna says it won’t enforce Covid vaccine patents during pandemic


 

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular